Poojitha Kolluri
Family Medicine · Shelbyville, ILNPI 1306402870
Payments from drug & device makers
Across 115 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$329
- Novartis$273
- Novo Nordisk$258
- Amgen$229
- Lilly USA, LLC$165
- Sumitomo Pharma America, Inc.$155
- plus $550 from 13 others
What the payments were for
- Food & beverage$1,959100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $329 |
| Novartis | 13 | $273 |
| Novo Nordisk | 19 | $258 |
| Amgen | 15 | $229 |
| Lilly USA, LLC | 9 | $165 |
| Sumitomo Pharma America, Inc. | 8 | $155 |
| AstraZeneca | 7 | $106 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Bayer | 5 | $97 |
| Boehringer Ingelheim | 3 | $65 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $30 |
| Pfizer | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Merck | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| GSK | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,959 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 164 | $122,602 |
| EliquisApixaban | 100 | $67,521 |
| MounjaroTirzepatide | 45 | $46,590 |
| TrulicityDulaglutide | 32 | $40,989 |
| RybelsusSemaglutide | 38 | $35,846 |
| FarxigaDapagliflozin Propanediol | 58 | $34,306 |
| TradjentaLinagliptin | 35 | $21,826 |
| XareltoRivaroxaban | 35 | $18,676 |
| JanuviaSitagliptin Phosphate | 30 | $16,843 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,970 |
| LinzessLinaclotide | 24 | $15,412 |
| MyrbetriqMirabegron | 20 | $12,055 |
| TrulancePlecanatide | 16 | $11,214 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $7,758 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $6,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $65 | $144,428199 claims |
| Lilly USA, LLCMounjaro, Trulicity | $165 | $87,57977 claims |
| PfizerEliquis | $25 | $67,521100 claims |
| AstraZenecaFarxiga, Symbicort | $106 | $36,56669 claims |
| Novo NordiskRybelsus | $258 | $35,84638 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta | $14 | $24,62453 claims |
| Johnson & JohnsonXarelto | $13 | $18,67635 claims |
| MerckJanuvia | $15 | $16,84330 claims |
| AbbVieLinzess | $329 | $15,41224 claims |
| Astellas Pharma US IncMyrbetriq | $30 | $12,05520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Shelbyville
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.